Monitor for any future board decision to implement the reverse split if the stock price approaches the $1.00 minimum bid threshold. The large increase in authorized equity plan shares signals potential future equity grants or employee retention awards, which could create overhang. No immediate trading catalyst.
Price Chart
Executive Summary
Bluejay Diagnostics held its 2026 annual meeting on June 9, 2026. Stockholders approved a reverse stock split authorization (ratios 1:2 to 1:20, valid through June 2027) and an amendment to the 2021 Stock Plan increasing authorized shares from 61 to 600,061. The board stated it has no present intention to implement the reverse split within the next 12 months, and the company is currently in compliance with Nasdaq listing requirements.
Key Facts
- Stockholders approved a reverse stock split authorization at ratios between 1-for-2 and 1-for-20, effective through June 9, 2027.
- The Board has no present intention to implement the reverse split during the 12-month period following approval.
- Stockholders approved Amendment No. 1 to the 2021 Stock Plan, increasing shares reserved for issuance from 61 to 600,061.
- All five director nominees were re-elected with strong support (approx. 90% of votes cast).
- Wolf & Company, P.C. was ratified as independent auditor for FY 2026.
- As of June 9, 2026, the closing price was $4.50 and the company was in compliance with all Nasdaq listing requirements.
Financial Impact
The stock plan amendment increases potential dilution by up to 600,000 shares (approx. 58% of current 1,034,715 shares outstanding). The reverse split authorization provides a tool to maintain Nasdaq listing but is not currently being exercised.
Risk Factors
- Potential future dilution of up to ~58% from the expanded stock plan.
- If the stock price declines significantly, the board may implement the reverse split, which is often viewed negatively by the market.
- The reverse split authorization is a defensive measure against potential delisting, signaling fragility in the stock price.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-066896 |
| Document: ea0294209-8k_bluejay.htm | 0001213900-26-066896 |
| Document: 0001213900-26-066896-index-headers.html | 0001213900-26-066896 |
| Document: 0001213900-26-066896-index.html | 0001213900-26-066896 |
| Document: 0001213900-26-066896.txt | 0001213900-26-066896 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | 8-K | $0.8323 | awaiting T+20 | — | $0.5850 (−29.71%) |
Oct 6, 2026 20d ago | 8-K | $0.8107 | awaiting T+20 | — | $0.5850 (−27.84%) |
Aug 13, 2026 10w ago | 8-K | $1.06 | awaiting T+20 | — | $0.5850 (−44.81%) |
Aug 13, 2026 10w ago | Press Release | $1.06 | awaiting T+20 | — | $0.5850 (−44.81%) |
Jul 22, 2026 13w ago | 8-K | $1.14 $0.9393 | ▼ −17.61% | ▼ −20.91% | $0.5850 (−48.68%) |
Jul 13, 2026 15w ago | 3 | $1.22 $0.9872 | ▼ −19.08% | ▼ −22.27% | $0.5850 (−52.05%) |
Jul 10, 2026 15w ago | 3 | $1.45 $1.07 | ▼ −26.21% | ▼ −28.63% | $0.5850 (−59.66%) |
Jun 29, 2026 17w ago | EFFECT | $1.44 $1.03 | ▲ +28.47% | ▲ +28.19% | $0.5850 (+59.38%) |
Jun 17, 2026 18w ago | S-3 | $4.46 $1.30 | ▲ +70.85% | ▲ +71.39% | $0.5850 (+86.88%) |
Jun 9, 2026 19w ago | 8-K | $4.49 $1.40 | ▼ −68.82% | ▼ −72.44% | $0.5850 (−86.97%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers